Showing results (21-30 of 75) with videos related to

Sort By:
Pageof 8
Asia-Pacific Journal of Clinical Oncology|June 23, 2021
Dismal outcome of relapsed or primary refractory adult T-cell lymphoblastic lymphoma: A retrospective study from ChinaHaizhu Chen, Yan Qin, Jianliang Yang, et al.
Cancer Chemotherapy and Pharmacology|July 19, 2014
Phase I clinical trial of pegylated liposomal mitoxantrone plm60-s: pharmacokinetics, toxicity and preliminary efficacyJianliang Yang, Yuankai Shi, Chunlei Li, et al.
Zhonghua Zhong Liu Za Zhi [Chinese Journal of Oncology]|December 31, 2015
[Efficacy and safety evaluation of gemcitabine combined with ifosfamide in patients with advanced nasopharyngeal carcinoma after failure of platinum-based chemotherapy]Shaoxuan Hu, Xiaohui He, Mei Dong, et al.
Leukemia & Lymphoma|July 23, 2021
Low platelet/platelet distribution width and high platelet/lymphocyte ratio are adverse prognostic factors in patients with newly diagnosed advanced Hodgkin lymphomaYunxia Tao, Xiaohui He, Yan Qin, et al.
Journal of Pharmaceutical and Biomedical Analysis|December 11, 2021
Development and validation of a UPLC-MS/MS method to quantitate anti-PD1 monoclonal antibody (Toripalimab), and comparison with electrochemiluminescence immunoassayShuxia Liu, Jianliang Yang, Sheng Yang, et al.
Zhonghua Zhong Liu Za Zhi [Chinese Journal of Oncology]|January 28, 2015
[Efficacy analysis of different follow-up methods in detecting first recurrence of lymphoma]Jianliang Yang, Yuankai Shi, Xiaohui He, et al.
Oncotarget|October 18, 2016
Prognostic value of pretreatment serum beta-2 microglobulin level in advanced classical Hodgkin lymphoma treated in the modern eraQin Wang, Yan Qin, Shengyu Zhou, et al.
Journal of Hematology & Oncology|December 19, 2024
Safety and efficacy of amulirafusp alfa (IMM0306), a fusion protein of CD20 monoclonal antibody with the CD47 binding domain of SIRPα, in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: a phase 1/2 studyJianliang Yang, Yongping Song, Keshu Zhou, et al.
Asia-Pacific Journal of Clinical Oncology|July 3, 2019
A prognostic nomogram constructed for relapsed or refractory diffuse large B-cell lymphoma patientsShiyu Jiang, Yan Qin, Peng Liu, et al.
Annals of Hematology|July 27, 2020
Event-free survival at 24 months is a robust surrogate endpoint for long-term survival in pediatric, adolescent, and adult T cell lymphoblastic lymphomaHaizhu Chen, Yan Qin, Jianliang Yang, et al.
Pageof 8